Moody’s Investors Service commented that the acquisition of Otezla by Amgen Inc. is credit negative based on a significant reduction in cash on hand and a rich multiple. There is no impact on Amgen’s Baa1/Prime-2 ratings or the stable rating outlook. For additional information please refer to Moody’s Issuer Comment on Amgen available on http://www.moodys.com.
blaineonline.finance.blog 